Original language | English |
---|---|
Pages (from-to) | 162–171 |
Number of pages | 9 |
Journal | The Lancet Gastroenterology & Hepatology |
Volume | 3 |
Issue number | 3 |
Early online date | 15 Dec 2017 |
DOIs | |
Publication status | Published - Mar 2018 |
Bibliographical note
This study was funded by the UK Medical Research Council (MRC)and National Institute for Health Research (NIHR) Efficacy and
Mechanism Evaluation programme; Cancer Research UK; NIHR
Clinical Trials Research Network; Health and Care Research Wales
(and equivalent in devolved nations); and AstraZeneca Drug Supply
and Distribution. PQ, MS, and SR received programme grant
support from Yorkshire Cancer Research. PQ is an NIHR Senior
Investigator at the Department of Pathology Cardiff and Vale
University Health Board, All Wales Genetics Laboratories, Wales
Cancer Bank. The MRC Clinical Trials Unit at University College
London receives funding from the MRC (programme grant
MC_UU_12023/20).
Keywords
- colorectal cancer
- biomarkers
- therapeutic efficacy
- EGFR inhibitors